You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
騰盛博藥(02137.HK)持續跑贏疫苗股 股價逆市續漲29%成交創新高
新冠疫苗股今早仍以騰盛博藥-B(02137.HK)表現最好,股價四連升,最高見15.28元,創逾四個月高,現報14.16元,逆市續漲29%,成交續增至7,156萬股,已超過去年7月13日首掛日所創紀錄高位6,736萬股,涉資逾9.77億元。 三葉草生物(02197.HK)高見4.79元,現報4.55元,續升6%;開拓藥物(09939.HK)高見19.25元,現報18.5元,續升2.8%。然而,康希諾(06185.HK)反覆跌2%報75.45元;復星醫藥(02196.HK)反覆跌1.4%報32.25元。藍籌藥明生物(02269.HK)三連跌,現報78.1元,續跌2.4%。 深圳市第三人民醫院院長盧洪洲教授上週五(8日)在騰盛博藥與媒體溝通會上表示,騰盛首款國產長效新冠中和抗體聯合治療藥物安巴韋單抗注射液(BRII-196)及羅米司韋單抗注射液(BRII-198)(簡稱:聯合療法)或仍對奧密克戎變異株BA.4、BA.5有效,他們於實現商業放行日(7日)拿到最新研究數據已證實了這一點。騰盛博藥總裁兼大中華區總經理、騰盛華創首席執行官羅永慶當日透露,上述新冠中和抗體聯合療程價格目前於內地定價1萬元人民幣之內。 恆指最低見21,088,現報21,139,下挫586點或2.7%,成交額623億元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account